Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas, confirmed through a tissue or cell sample
- People who have at least one tumour that can be measured using standard imaging guidelines (RECIST v1.1)
- People whose general health and ability to carry out daily activities falls within a certain range on a standard scale (ECOG score of 0, 1, or 2 — confirm with trial site)
- People with a life expectancy of more than 12 weeks
- People whose bone marrow, kidneys, and liver are functioning adequately at the time of screening
Who may not be able to join:
- People who have previously received treatment for locally advanced or metastatic pancreatic cancer
- People who have had major surgery recently at the time of screening (confirm with trial site for timeframe)
- People with brain metastases (cancer that has spread to the brain) that are not well controlled
- People with an active bacterial infection
- People who have or have had another type of cancer, other than certain skin cancers (basal cell carcinoma), early-stage cervical cancer (carcinoma in situ), or papillary thyroid cancer
- People who are pregnant, planning to become pregnant, or breastfeeding
- People with HIV, or active hepatitis B or C infection
- People who have had a severe allergic reaction to either BEY1107 or Gemcitabine (the study drugs)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-42-716-0020
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MTD & Safety assessment (Phase I); DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.